Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients
Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients
Read moreThu, 29th Aug 2019 09:12
Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients
Read more(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.
Read more(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.
Read moreStudy Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival
Read more(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.
Read moreAngle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreAngle Eyes US Consent For Parsortix Cancer Medication In Third Quarter
Read moreAngle Gets Study Results Demonstrating Use Of Parsortix In Melanoma
Read moreAngle Submits Positive Test Results For Parsortix System To US FDA
Read more(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.
Read moreAngle Notes Queen Mary University's European Cancer Prognosis Patent
Read more(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it
Read more(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study
Read more